Cerebrovascular diseases
-
Cerebrovascular diseases · Jan 2006
New modalities and aspects of antiplatelet therapy for stroke prevention.
Antiplatelet therapy is indicated for secondary prevention of ischaemic stroke. The first-line antiplatelet agent is aspirin. ⋯ Strategies against aspirin resistance may include alternative use of other antiplatelet agents, combination of aspirin with other antiplatelet agents and investigation into molecular targets to develop novel antiplatelet agents. Progress in antiplatelet therapy should be directed at further reducing the risk of ischaemic events including ischaemic stroke without increasing the risk of haemorrhagic events including haemorrhagic stroke.
-
Cerebrovascular diseases · Jan 2006
Serial measurements of N-terminal pro-brain natriuretic peptide after acute ischemic stroke.
The exact time-course of N-terminal pro-brain natriuretic peptide (NT-proBNP) and the prognostic importance in the immediate phase of ischemic stroke have not been established. ⋯ NT-proBNP peaks the day after onset of symptoms in patients with acute ischemic stroke. A single measurement of NT-proBNP appears to be an indicator of 6-month mortality.
-
Cerebrovascular diseases · Jan 2006
Comparative StudyDirect costs of surgical clipping and endovascular coiling of unruptured intracranial aneurysms.
Unruptured intracranial aneurysms can be preventively treated by surgical clipping or endovascular coiling. We determined in detail the costs of these treatments. ⋯ For unruptured intracranial aneurysms, direct in-hospital costs of coiling are on average higher than those of clipping, mostly because of the more expensive coils.
-
Cerebrovascular diseases · Jan 2006
Randomized Controlled Trial Multicenter StudyCiticoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study.
In experimental models citicoline has shown beneficial effects in intracerebral haemorrhage. Citicoline is a neuroprotectant drug with some beneficial effects in human ischaemic stroke and with an excellent safety profile. We decided to carry out a pilot study to test its safety and efficacy in human intracerebral haemorrhaging. ⋯ Citicoline seems to be a safe drug in human intracerebral haemorrhage with a positive trend regarding efficacy. These data should be confirmed in a larger trial.